The aryl hydrocarbon receptor: A diagnostic and therapeutic target in glioma

Ting Xiang Lim; Muneer Ahamed; David C. Reutens

doi:10.1016/j.drudis.2021.09.021

The aryl hydrocarbon receptor: A diagnostic and therapeutic target in glioma

Ting Xiang Lim, Muneer Ahamed, David C. Reutens

Research output: Contribution to journal › Review article › peer-review

9 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is a deadly disease; 5-year survival rates have shown little improvement over the past 30 years. In vivo positron emission tomography (PET) imaging is an important method of identifying potential diagnostic and therapeutic molecular targets non-invasively. The aryl hydrocarbon receptor (AhR) is a transcription factor that regulates multiple genes involved in immune response modulation and tumorigenesis. The AhR is an attractive potential drug target and studies have shown that its activation by small molecules can modulate innate and adaptive immunity beneficially and prevent AhR-mediated tumour promotion in several cancer types. In this review, we provide an overview of the role of the AhR in glioma tumorigenesis and highlight its potential as an emerging biomarker for glioma therapies targeting the tumour immune response and PET diagnostics.

Original language	English
Pages (from-to)	422-435
Number of pages	14
Journal	Drug Discovery Today
Volume	27
Issue number	2
DOIs	https://doi.org/10.1016/j.drudis.2021.09.021
Publication status	Published or Issued - Feb 2022
Externally published	Yes

Keywords

AhR
Biomarker
GBM
Immunotherapy
PET imaging

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2021.09.021

Cite this

@article{c5d6a6513ea34d8385428cd82076a408,

title = "The aryl hydrocarbon receptor: A diagnostic and therapeutic target in glioma",

abstract = "Glioblastoma multiforme (GBM) is a deadly disease; 5-year survival rates have shown little improvement over the past 30 years. In vivo positron emission tomography (PET) imaging is an important method of identifying potential diagnostic and therapeutic molecular targets non-invasively. The aryl hydrocarbon receptor (AhR) is a transcription factor that regulates multiple genes involved in immune response modulation and tumorigenesis. The AhR is an attractive potential drug target and studies have shown that its activation by small molecules can modulate innate and adaptive immunity beneficially and prevent AhR-mediated tumour promotion in several cancer types. In this review, we provide an overview of the role of the AhR in glioma tumorigenesis and highlight its potential as an emerging biomarker for glioma therapies targeting the tumour immune response and PET diagnostics.",

keywords = "AhR, Biomarker, GBM, Immunotherapy, PET imaging",

author = "Lim, {Ting Xiang} and Muneer Ahamed and Reutens, {David C.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = feb,

doi = "10.1016/j.drudis.2021.09.021",

language = "English",

volume = "27",

pages = "422--435",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - The aryl hydrocarbon receptor

T2 - A diagnostic and therapeutic target in glioma

AU - Lim, Ting Xiang

AU - Ahamed, Muneer

AU - Reutens, David C.

PY - 2022/2

Y1 - 2022/2

N2 - Glioblastoma multiforme (GBM) is a deadly disease; 5-year survival rates have shown little improvement over the past 30 years. In vivo positron emission tomography (PET) imaging is an important method of identifying potential diagnostic and therapeutic molecular targets non-invasively. The aryl hydrocarbon receptor (AhR) is a transcription factor that regulates multiple genes involved in immune response modulation and tumorigenesis. The AhR is an attractive potential drug target and studies have shown that its activation by small molecules can modulate innate and adaptive immunity beneficially and prevent AhR-mediated tumour promotion in several cancer types. In this review, we provide an overview of the role of the AhR in glioma tumorigenesis and highlight its potential as an emerging biomarker for glioma therapies targeting the tumour immune response and PET diagnostics.

AB - Glioblastoma multiforme (GBM) is a deadly disease; 5-year survival rates have shown little improvement over the past 30 years. In vivo positron emission tomography (PET) imaging is an important method of identifying potential diagnostic and therapeutic molecular targets non-invasively. The aryl hydrocarbon receptor (AhR) is a transcription factor that regulates multiple genes involved in immune response modulation and tumorigenesis. The AhR is an attractive potential drug target and studies have shown that its activation by small molecules can modulate innate and adaptive immunity beneficially and prevent AhR-mediated tumour promotion in several cancer types. In this review, we provide an overview of the role of the AhR in glioma tumorigenesis and highlight its potential as an emerging biomarker for glioma therapies targeting the tumour immune response and PET diagnostics.

KW - AhR

KW - Biomarker

KW - GBM

KW - Immunotherapy

KW - PET imaging

UR - http://www.scopus.com/inward/record.url?scp=85118335039&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2021.09.021

DO - 10.1016/j.drudis.2021.09.021

M3 - Review article

C2 - 34624509

AN - SCOPUS:85118335039

SN - 1359-6446

VL - 27

SP - 422

EP - 435

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 2

ER -

The aryl hydrocarbon receptor: A diagnostic and therapeutic target in glioma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this